3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
24
Colorectal Neoplasms
16
Small Cell Lung Carcinoma
6
Stomach Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Recurrence
3
Rectal Neoplasms
3
Osteosarcoma
3
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Wilms Tumor
1
Weight Loss
1
Triple Negative Breast Neoplasms
1
Somatostatinoma
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Small Bowel Adenocarcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Interventions
Fulvestrant
5
dalpiciclib
3
Letrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
exemestane
2
apatinib
2
Anastrozole
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liposomes
1
Irinotecan
1
Ga(III)-DOTATOC
1
Everolimus
1
Cell Separation
1
Capecitabine
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Cancer Metastatic
×
irinotecan sucrosofate
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled